Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Cullinan Therapeutics (CGEM) Capital Expenditures (2020 - 2023)

Cullinan Therapeutics has reported Capital Expenditures over the past 3 years, most recently at $49000.0 for Q2 2023.

Quarterly results put Capital Expenditures at $49000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $208000.0 (down 81.64% YoY), and the annual figure for FY2025 was $49000.0, changed.
Capital Expenditures for Q2 2023 was $49000.0 at Cullinan Therapeutics, down from $159000.0 in the prior quarter.
Over the last five years, Capital Expenditures for CGEM hit a ceiling of $882000.0 in Q4 2022 and a floor of -$1000.0 in Q4 2020.
Median Capital Expenditures over the past 3 years was $26500.0 (2020), compared with a mean of $168875.0.